BZYR
Burzynski Research Institute, Inc. [BZYR] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BZYR Stock Summary
In the News
BZYR Financial details
Company Rating
-
Market Cap
4.55M
Income
-272.23K
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
31 May 2023
P/E
-62.97
Forward P/E
-
PEG
8.79
P/S
-
P/B
-1292.17
P/C
-
P/FCF
-18.9
Quick Ratio
0.22
Current Ratio
0.29
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0
EPS next Y
-
EPS next Q
-
EPS this Y
-5.41%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
73.68%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-20%
Inst Own
-
Inst Trans
-
ROA
-5112%
ROE
319%
ROC
225.23%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.013-0.086
52W High
-
52W Low
-
RSI
69.4
Rel Volume
0.55
Avg Volume
5.41K
Volume
3K
Perf Week
77.1%
Perf Month
1.67%
Perf Quarter
52.5%
Perf Half Y
77.1%
-
-
-
-
Beta
1.478
-
-
Volatility
0.01%, 0.01%
Prev Close
48.38%
Price
0.0549
Change
26.79%
Company Profile
- Volume Average 5.41K
- Market Capitalization 4.55M
- CEO Dr. Stanislaw R. Burzynski M.D., Ph.D.
- Headquarters Houston,TX,US
- IPO Date 1997-01-02
-
Website
https://www.burzynskiclinic.com 
Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs to treat cancer. The company is also involved in the production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services. Burzynski Research Institute, Inc. was founded in 1977 and is based in Houston, Texas.
